Third generation EGFR TKIs: current data and future directions
Chee‐Seng Tan, Nesaretnam Barr Kumarakulasinghe, Yiqing Huang et al. · Molecular Cancer · 2018
Acquired T790 M mutation is the commonest cause of resistance for advanced non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutant patients who had progressed after first line EGFR TKI (tyrosine kinase inhibitor). Several third generation EGFR TKIs which are EGFR mutant selective and wild-type (WT) sparing were developed to treat these patients with T790 M acquired resistant mutation. Osimertinib is one of the third generation EGFR TKIs and is currently the most advanced in clinical development. Unfortunately, despite good initial response, patients who was treated with third generation EGFR TKI would develop acquired resistance and several mechanisms had been identified and the commonest being C797S mutation at exon 20. Several novel treatment options were being developed for patients who had progressed on third generation EGFR TKI but they are still in the early phase of development. Osimertinib under FLAURA study had been shown to have better progression-free survival over first generation EGFR TKI in the first line setting and likely will become the new standard of care.
Cited by 311 works. doi:10.1186/s12943-018-0778-0 Open-access PDF
Authors
- Chee‐Seng Tan
- Nesaretnam Barr Kumarakulasinghe
- Yiqing Huang
- Yvonne Li En Ang
- Joan Rou-En Choo
- Boon-Cher Goh
- Ross Andrew Soo
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer